Advisory Board

Sandip Sarkar

FRCS, MA, PhD
Specialist Advisor

After graduating from Cambridge University, Mr Sarkar underwent medical training at the United Medical and Dental Schools of Guys and St Thomas’ in London. His higher surgical training was through the London Deanery, when he gained his Fellowship of the Royal College of Surgeons. His PhD (University College London) was awarded in Vascular surgery and his Certificate of Completion of Training in General Surgery.

He has published widely in nanocomposite compliant graft development as well as arterial tissue engineering. As a specialist Vascular and Endovascular Surgeon at The Royal London Hospital, Barts Health NHS Trust; he has established a pioneering complex diabetic foot multidisciplinary unit and has an interest in wound management and amputation avoidance.

Chris Astle

CA, MChem, PhD, NED
Non-Executive Director

A Chartered Accountant with experience in the healthcare industry as a senior finance leader. Currently, founder and CEO of Think Forwards. Prior role as CFO International Markets for Allergan Inc. Resident CFO at the Finance Director Magazine, Chair of the CFO Agenda Conference 2018, guest lecturer and tutor at the Henley School of Management, and judge at the British Accountant Awards.

Dr Rick Morton B.Sc (Hons) PhD, NED Chief Medical Affairs Officer

Dr Rick Morton

B.Sc (Hons) PhD, NED
Chief Medical Affairs Officer

Rick Morton is the Global Chief Medical Affairs Officer at WPP Health Wellness and has extensive academic, biopharmaceutical industry and global healthcare experience. Passionate about the critical role of medical affairs and market access in the planning and execution of pre, peri and post-launch patient-centric strategies that guide effective value-based healthcare product development and commercialization.

Dr Pete Clausen

PhD,
Scientific Advisor

Pete is currently the Chief Scientific Officer for Nuo Therapeutics Inc focused on the development of autologous stem cell technologies and the commercialization of medical devices for the orthopaedic and chronic wound markets. He has more than 25 years of experience in biotechnology having worked within both the US National Institutes of Health and the commercial biotech industry to develop small molecule, peptide and stem cell-based therapies in the areas of inflammatory mediated disease and stem cell transplantation.